Key facts
- It has raised $95.0M; the latest was Early Stage VC ($91.0M) in Oct 2025.
- Notable investors include F-Prime Capital, BGF (Financial Services), Cambridge Enterprise Ventures, Sofinnova Partners, Digitalis Ventures — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for T-Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for T-Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About T-Therapeutics
Operator of a biopharmaceutical company intended to develop engineered soluble biologics for oncological and immunological indications. The company's proprietary T cell receptors (TCR) discovery platform, a very heavily humanised mouse, which gives access to TCRs for human antigens that are not available from human samples, binds specific pMHC targets on target cells and recruits T cells to kill cancers or dampen down an immune response, enabling patients to improve their lives with chronic and infectious diseases.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2022
- Employees
- 66
- Website
- t-therapeutics.com/
- Ownership
- Privately Held (backing)
T-Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in T-Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on T-Therapeutics in its N-PORT filings yet. We sweep new filings monthly.